In focus
Latest feed
Nektar Therapeutics Charts a Course Forward: Q2 2026 Sees Strategic Investment Amidst Financial Shifts
Elicio Therapeutics Navigates Q2 2026 with Strong Financing and Promising Clinical Signals
Elicio Therapeutics Marks Significant Financial Turnaround and Pivotal Clinical Advances in Latest Quarter
Step Into a Floral Dreamscape: Tel Aviv's Enchanting 'Journey Between Worlds' Exhibition
